Loading clinical trials...
Loading clinical trials...
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
Age
15 - 50 years
Sex
FEMALE
Healthy Volunteers
No
Ascendis Investigational Site
Morgantown, West Virginia, United States
Start Date
February 18, 2026
Primary Completion Date
January 1, 2036
Completion Date
January 1, 2036
Last Updated
March 2, 2026
50
ESTIMATED participants
Palopegteriparatide
DRUG
Lead Sponsor
Ascendis Pharma A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07197450